FDA grants breast cancer approval to Roche’s Perjeta/Herceptin combo therapy
pharmafile | December 21, 2017 | News story | Sales and Marketing | Cancer, FDA, Herceptin, Perjeta, Roche, breast cancer, pharma
Roche has announced that the FDA has granted approval to Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and a (Perjeta-based) chemotherapy regimen for the adjuvant treatment of HER2-positive early breast cancer which is at a high chance of recurrence.
The FDA based its decision on Phase 3 data which showed that the regimen in question was more effective than Herceptin and chemotherapy alone, cutting the risk of invasive breast cancer recurrence or death by 18%.
As part of the appraisal, the US regulator also converted the previously granted accelerated approval of the Perjeta-based regimen to full approval for neoadjuvant treatment of HER2-positive, locally advanced, inflammatory, or early stage breast cancer.
The regimen is to be administered to patients for a full year, and those receiving the neoadjuvant Perjeta-based regimen are advised to continue Perjeta and Herceptin after surgery to complete a full year’s treatment.
“The goal of treating breast cancer early is to provide people with the best chance for a cure. While we come closer to this goal with each advance, many people still have a recurrence and progress to the metastatic stage,” commented Roche’s Chief Medical Officer and Head of Global Product Development, Sandra Horning. “Today’s approval of Perjeta means people with HER2-positive early breast cancer at high risk of recurrence have a new, clinically meaningful treatment option to reduce the chances of their disease returning.”
Matt Fellows
Related Content
Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
Alto Neuroscience’s schizophrenia treatment granted FDA Fast Track designation
Alto Neuroscience has announced that its investigational treatment for cognitive impairment associated with schizophrenia (CIAS) …
